Fig. 1: Prevalence of CSF AD/LB groups in clinical and post-mortem populations.
From: Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease
A Barplots illustrate the prevalence of AD/LB groups across the whole cohort and split by MCI and dementia individuals. AD+ is defined as CSF p-tau181/Aβ42 positive and LB+ as α-synuclein SAA positive. B CSF AD/LB groups distribution within the post-mortem subpopulation is shown across neuropathological scores of regional distribution of Lewy body pathology, amyloid plaque Thal stages, neuritic plaques CERAD grading, tau Braak stages, and presence of TDP-43 in the hippocampus.
